2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2005010108v1 16/12/3507    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kadereit, B. Articles by Mohaupt, M. G. Search for Related Content PubMed PubMed Citation Articles by Kadereit, B. Articles by Mohaupt, M. G. Related Collections Related Article

Extracellular ATP Determines 11-Hydroxysteroid Dehydrogenase Type 2 Activity via Purinergic Receptors

Department of Nephrology/Hypertension, University of Berne, Berne, Switzerland

Address correspondence to: Dr. Markus G. Mohaupt, University Hospital Berne, Department of Nephrology/Hypertension, Freiburgerstr. Inselspital, 3010 Berne, Switzerland. Phone: +41-31-632-9731; Fax: +41-31-632-9734; E-mail: markus.mohaupt{at}insel.ch

Received for publication January 26, 2005. Accepted for publication September 9, 2005.

Hypertension and sodium retention are features of a diminished 11-hydroxysteroid dehydrogenase type 2 (11-HSD2). The activity of this enzyme is reduced in various disease states with abnormal renal sodium retention and hypertension, including preeclampsia. ATP release to the extracellular compartment is observed with shear stress, inflammation, and placental ischemia. It was hypothesized that ATP downregulates 11-HSD2 activity. For that purpose, cell lines from different tissues that previously were used to study the regulation of 11-HSD2 were investigated: JEG-3, a vascular trophoblastic; LLCPK1, a renal tubular; and SW620, a colonic epithelial cell line. The 11-HSD2 activity, assessed by the conversion of ³H-cortisol to cortisone, was reversibly reduced during incubation with ATP or its stable analogue ATPS in intact JEG-3 and LLCPK1, but not in SW620 cells. In JEG-3 cells, the purinergic antagonist pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid but not suramin reversed the inhibition. Incubation with UTP and ADP and their degradation products including adenosine and ,-methylene-ATP did not inhibit 11-HSD2 activity. In contrast, 11-HSD2 activity increased almost 2.5-fold after incubation with 2'-methylthio-ATP. This indicates a bidirectional regulation by nucleotides via purinergic receptors. In JEG-3 cells, ATP/ATPS did not alter 11-HSD2 promoter activity but reduced 11-HSD2 protein and mRNA concentration and half-life, suggesting a posttranscriptional regulation. In conclusion, ATP inhibits cell type specifically via purinergic receptors the expression and activity of the 11-HSD2 by a posttranscriptional mechanism.

Related Article

This Month’s Highlights
J. Am. Soc. Nephrol. 2005 16: 3447-3448. [Full Text] [PDF]

This article has been cited by other articles:

				A. Grenz, H. Zhang, M. Hermes, T. Eckle, K. Klingel, D. Y. Huang, C. E. Muller, S. C. Robson, H. Osswald, and H. K. Eltzschig Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury FASEB J, September 1, 2007; 21(11): 2863 - 2873. [Abstract] [Full Text] [PDF]

				S. A. Reini, C. E. Wood, E. Jensen, and M. Keller-Wood Increased maternal cortisol in late-gestation ewes decreases fetal cardiac expression of 11beta-HSD2 mRNA and the ratio of AT1 to AT2 receptor mRNA Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2006; 291(6): R1708 - R1716. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673